Verification evidence is still being completed.
PDF / print export
Ascendis Pharma
Hellerup, Denmark
- Verified lead
- Jan Mikkelsen
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- President and Chief Executive Officer
- 2026 technical specialization
- TransCon Endocrinology and Rare-Disease Therapeutics
- Review cycle
- May 2026
- Full address
- Tuborg Boulevard 12, DK-2900 Hellerup, Denmark
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Ascendis Pharma management page confirming Jan Mikkelsen as President and Chief Executive Officer.
- Editorial note
- Ascendis Pharma adds a source-backed Hellerup headquarters record with attributable CEO coverage and current public-company governance materials.
TransCon Endocrinology and Rare-Disease Therapeutics
Commercial biopharma governance and quality oversight, Rare-disease portfolio operations
Ascendis Pharma adds a source-backed Hellerup headquarters record with attributable CEO coverage and current public-company governance materials.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated07 Jul 2026, 01:10
Company profile · Hellerup, Denmark
Ascendis Pharma
TransCon Endocrinology and Rare-Disease Therapeutics · Global biopharma development and commercialization
Verified 15 Mar 2026 · 3 sources
Commercial
Ascendis Pharma adds a source-backed Hellerup headquarters record with attributable CEO coverage and current public-company governance materials.
Contact & location
- Website
- ascendispharma.com
- Company page
- Lead
- Jan Mikkelsen (verified ↗)
- Compliance
- Not yet on record
- Last reviewed
- 15 Mar 2026 (4mo ago)
- Scale
- Global biopharma development and commercialization
- Capabilities
- TransCon Platform Development · Endocrinology and Rare-Disease Programs · Global Commercial Operations
- Founded
- 2007
- Headcount
- 501-1000
TransCon Endocrinology and Rare-Disease Therapeutics
Ascendis Pharma adds a source-backed Hellerup headquarters record with attributable CEO coverage and current public-company governance materials.
Editorial note
Ascendis Pharma adds a source-backed Hellerup headquarters record with attributable CEO coverage and current public-company governance materials.
Current review cycleMarch 2026
Verification details
Clinical profileSTATUS: VERIFIED MARCH 2026
Jan Mikkelsen
President and Chief Executive Officer
Full addressTuborg Boulevard 12, DK-2900 Hellerup, Denmark
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Physical site source
Ascendis Pharma contact page listing Tuborg Boulevard 12 in Hellerup.
Open sourceGlobal biopharma development and commercialization
Hellerup, Denmark. TransCon Endocrinology and Rare-Disease Therapeutics. Review completed on 15 Mar 2026.
Danish and international pharmaceutical oversight
Commercial biopharma governance and quality oversight, Rare-disease portfolio operations
Capabilities
TransCon Platform Development
Endocrinology and Rare-Disease Programs
Global Commercial Operations
Sources
The official sources used to verify this profile.
Infrastructure
Program governance systems
Global regulatory platforms
Commercial operations infrastructure
Certifications
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Review log
15 Mar 2026: Executive identity confirmed via official management disclosure.
15 Mar 2026: Trust review remains in progress.
Frequently asked questions
- Where is Ascendis Pharma located?
- Ascendis Pharma operates from Tuborg Boulevard 12, DK-2900 Hellerup, Denmark, Hellerup, Denmark.
- Who runs Ascendis Pharma?
- Ascendis Pharma is led by Jan Mikkelsen, President and Chief Executive Officer. Verified 15 Mar 2026.
- What does Ascendis Pharma do?
- Ascendis Pharma adds a source-backed Hellerup headquarters record with attributable CEO coverage and current public-company governance materials. Core capabilities: TransCon Platform Development, Endocrinology and Rare-Disease Programs, Global Commercial Operations.
Editorial context
Related technical briefs
Briefs that name Hellerup as a covered market or city.